

Connecticut Medicaid Medical Assistance Program Oversight Council Adult Task Force of the QI Committee

Minutes of the January 29, 2013 Meeting

Attendance: Mag Morelli (Chair), Steve Colangelo, Debbie Poerio, and Cindy Kozak

Charge of the Task Force:

Choose an indicator from the HEDIS list to focus on; research the health issue more thoroughly to identify recommended ways to address any concerns and improve quality; and provide those recommendations to the larger QI Committee.

The task force previously determined that they would look into the issue of adult patients receiving appropriate follow-up visits after being prescribed an anti-depressant medication to treat a new medical diagnosis of depression. This initial project would be kept simple and the follow up with the QI Committee after initial recommendations are made would help the task force members determine the ongoing role of the task force.

DSS was asked to gather specific data for the task force to review at this meeting so that they might develop a report and recommendation for the QI Committee. The task force reviewed the following draft data results presented by DSS:

Criteria for Inclusion in Analysis:

- 1) Depression medication prescribed at a PCP visit in the first quarter of 2012.*
- 2) No diagnosis of depression in the 4 months prior to prescription date.*
- 3) No depression medication prescribed in the 4 months prior to the prescription date.*
- 4) Member was between 21 and 64 years old at time of prescription*

Criteria for meeting measure goal:

- 1) Within 90 days client should have had a follow up visit with a PCP or mental health professional with prescribing privileges.*

Results:

53% of those that had a PCP Visit and were prescribed a depression medication had a visit with either a PCP or mental health professional with prescription privileges within 90 days.

26% had no follow up visit and no longer had an active prescription by the end of the 90 days.

21% did not have a follow up visit even though they still had an active prescription at the end of the 90 days.

The task force discussed that this was compelling information to provide to the QI Committee for their review and discussion with Value Options. However, before this

would be done, DSS was asked to find out for the 21% who did not have a follow up visit, but had an active prescription after 90 days, who the prescriber was for the last prescription refill. The information will be reviewed at the next task force meeting and then a report sent to Committee.

Future Meeting Dates: Last Wednesday of every month at 10 a.m.